Study of D-2570 in Subjects With Non-Segmental Vitiligo
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07625891, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- InventisBio Co., Ltd
- Trial code
- NCT07625891
- Record updated
- 15 July 2026
- Original description
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.Read full original descriptionShow less
A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
Inclusion: Voluntarily signs informed consent and complies with study procedures; Age 18-65 years, male or female; Clinical diagnosis of non-segmental vitiligo at screening; F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo; Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.
Exclusion: - Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment; Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing; Active, latent or inadequately treated tuberculosis infection; Positive HIV, active HBV/HCV infection, or untreated syphilis; Current or history of severe herpes infection; Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment; Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study; Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders; Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months; Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia); History of severe drug hypersensitivity or drug-related toxicity; Any condition that may impair protocol compliance or study participation per investigator judgment; Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts; Over 33% facial or total vitiligo lesions with leukotrichia; Pregnant or breastfeeding females.